356 related articles for article (PubMed ID: 26215061)
1. The development of a clinical score for the prediction of nonalcoholic steatohepatitis in patients with nonalcoholic fatty liver disease using routine parameters.
Chunming L; Jianhui S; Hongguang Z; Chunwu Q; Xiaoyun H; Lijun Y; Xuejun Y
Turk J Gastroenterol; 2015 Sep; 26(5):408-16. PubMed ID: 26215061
[TBL] [Abstract][Full Text] [Related]
2. Diagnostic value of alcoholic liver disease (ALD)/nonalcoholic fatty liver disease (NAFLD) index combined with γ-glutamyl transferase in differentiating ALD and NAFLD.
Wang J; Li P; Jiang Z; Yang Q; Mi Y; Liu Y; Shi R; Zhou Y; Wang J; Lu W; Li S; Liu D
Korean J Intern Med; 2016 May; 31(3):479-87. PubMed ID: 27025268
[TBL] [Abstract][Full Text] [Related]
3. [Value of serum osteoprotegerin in noninvasive diagnosis of nonalcoholic steatohepatitis].
Yang M; Liu Y; Zhou G; Guo X; Zou S; Liu S; Jiang L; Liu Y; Zhu L; Guo C; Zhao J
Zhonghua Gan Zang Bing Za Zhi; 2016 Feb; 24(2):96-101. PubMed ID: 26983475
[TBL] [Abstract][Full Text] [Related]
4. A novel model using mean platelet volume and neutrophil to lymphocyte ratio as a marker of nonalcoholic steatohepatitis in NAFLD patients: multicentric study.
Abdel-Razik A; Mousa N; Shabana W; Refaey M; ElMahdy Y; Elhelaly R; Elzehery R; Zalata K; Arafa M; Elbaz S; Hafez M; Awad M
Eur J Gastroenterol Hepatol; 2016 Jan; 28(1):e1-9. PubMed ID: 26469357
[TBL] [Abstract][Full Text] [Related]
5. Alanine Aminotransferase and Gamma-Glutamyl Transpeptidase Predict Histologic Improvement in Pediatric Nonalcoholic Steatohepatitis.
Newton KP; Lavine JE; Wilson L; Behling C; Vos MB; Molleston JP; Rosenthal P; Miloh T; Fishbein MH; Jain AK; Murray KF; Schwimmer JB;
Hepatology; 2021 Mar; 73(3):937-951. PubMed ID: 32416645
[TBL] [Abstract][Full Text] [Related]
6. Noninvasive estimation of disease activity and liver fibrosis in nonalcoholic fatty liver disease using anthropometric and biochemical characteristics, including insulin, insulin resistance, and 13C-methionine breath test.
Korkmaz H; Unler GK; Gokturk HS; Schmidt WE; Kebapcilar L
Eur J Gastroenterol Hepatol; 2015 Oct; 27(10):1137-43. PubMed ID: 26049707
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of circulating zonulin as a potential marker in the pathogenesis of nonalcoholic fatty liver disease.
Hendy OM; Elsabaawy MM; Aref MM; Khalaf FM; Oda AMA; El Shazly HM
APMIS; 2017 Jul; 125(7):607-613. PubMed ID: 28430371
[TBL] [Abstract][Full Text] [Related]
8. Plasma Pentraxin 3 Differentiates Nonalcoholic Steatohepatitis (NASH) from Non-NASH.
Boga S; Koksal AR; Alkim H; Yilmaz Ozguven MB; Bayram M; Ergun M; Sisman G; Tekin Neijmann S; Alkim C
Metab Syndr Relat Disord; 2015 Nov; 13(9):393-9. PubMed ID: 26367098
[TBL] [Abstract][Full Text] [Related]
9. A novel noninvasive diagnostic method for nonalcoholic steatohepatitis using two glycobiomarkers.
Kamada Y; Ono M; Hyogo H; Fujii H; Sumida Y; Mori K; Tanaka S; Yamada M; Akita M; Mizutani K; Fujii H; Yamamoto A; Takamatsu S; Yoshida Y; Itoh Y; Kawada N; Chayama K; Saibara T; Takehara T; Miyoshi E
Hepatology; 2015 Nov; 62(5):1433-43. PubMed ID: 26199205
[TBL] [Abstract][Full Text] [Related]
10. Limited utility of plasma M30 in discriminating non-alcoholic steatohepatitis from steatosis--a comparison with routine biochemical markers.
Chan WK; Sthaneshwar P; Nik Mustapha NR; Mahadeva S
PLoS One; 2014; 9(9):e105903. PubMed ID: 25184298
[TBL] [Abstract][Full Text] [Related]
11. A Simple Index for Nonalcoholic Steatohepatitis-HUFA-Based on Routinely Performed Blood Tests.
Culafic M; Vezmar Kovacevic S; Dopsaj V; Stulic M; Vlaisavljevic Z; Miljkovic B; Culafic D
Medicina (Kaunas); 2019 Jun; 55(6):. PubMed ID: 31163711
[No Abstract] [Full Text] [Related]
12. Predictive value of ALT levels for non-alcoholic steatohepatitis (NASH) and advanced fibrosis in non-alcoholic fatty liver disease (NAFLD).
Verma S; Jensen D; Hart J; Mohanty SR
Liver Int; 2013 Oct; 33(9):1398-405. PubMed ID: 23763360
[TBL] [Abstract][Full Text] [Related]
13. Lipoprotein A, combined with alanine aminotransferase and aspartate aminotransferase, contributes to predicting the occurrence of NASH: a cross-sectional study.
Zhang Y; He H; Zeng YP; Yang LD; Jia D; An ZM; Jia WG
Lipids Health Dis; 2020 Jun; 19(1):134. PubMed ID: 32527258
[TBL] [Abstract][Full Text] [Related]
14. Serum cytokeratin-18 fragment levels as noninvasive marker of nonalcoholic steatohepatitis in the chilean population.
Arab JP; Hernández-Rocha C; Morales C; Vargas JI; Solís N; Pizarro M; Robles C; Sandoval D; Ponthus S; Benítez C; Barrera F; Soza A; Riquelme A; Arrese M
Gastroenterol Hepatol; 2017; 40(6):388-394. PubMed ID: 28359548
[TBL] [Abstract][Full Text] [Related]
15. Combination of Aspartate Aminotranferase and Tumor Necrosis Factor-α as Non Invasive Diagnostic Tools for Non Alcoholic Steatohepatitis (NASH).
Purnomo HD; Mundhofir FE; Kasno ; Sudijanto E; Darmono ; Daldiyono ; Djokomoeljanto R; Faradz SM
Acta Med Indones; 2015 Jan; 47(1):16-23. PubMed ID: 25948763
[TBL] [Abstract][Full Text] [Related]
16. Correlation of alanine aminotransferase levels and a histological diagnosis of steatohepatitis with ultrasound-diagnosed metabolic-associated fatty liver disease in patients from a centre in Nigeria.
Kolawole OJ; Oje MM; Betiku OA; Ijarotimi O; Adekanle O; Ndububa DA
BMC Gastroenterol; 2024 May; 24(1):147. PubMed ID: 38724942
[TBL] [Abstract][Full Text] [Related]
17. Plasma cathepsin D levels: a novel tool to predict pediatric hepatic inflammation.
Walenbergh SM; Houben T; Hendrikx T; Jeurissen ML; van Gorp PJ; Vreugdenhil AC; Adriaanse MP; Buurman WA; Hofker MH; Mosca A; Lindsey PJ; Alisi A; Liccardo D; Panera N; Koek GH; Nobili V; Shiri-Sverdlov R
Am J Gastroenterol; 2015 Mar; 110(3):462-70. PubMed ID: 25732418
[TBL] [Abstract][Full Text] [Related]
18. New scoring system combining the FIB-4 index and cytokeratin-18 fragments for predicting steatohepatitis and liver fibrosis in patients with nonalcoholic fatty liver disease.
Tada T; Kumada T; Toyoda H; Saibara T; Ono M; Kage M
Biomarkers; 2018; 23(4):328-334. PubMed ID: 29308929
[TBL] [Abstract][Full Text] [Related]
19. Increased serum soluble lectin-like oxidized low-density lipoprotein receptor-1 levels in patients with biopsy-proven nonalcoholic fatty liver disease.
Ozturk O; Colak Y; Senates E; Yilmaz Y; Ulasoglu C; Doganay L; Ozkanli S; Oltulu YM; Coskunpinar E; Tuncer I
World J Gastroenterol; 2015 Jul; 21(26):8096-102. PubMed ID: 26185381
[TBL] [Abstract][Full Text] [Related]
20. High FIB-4 index as an independent risk factor of prevalent chronic kidney disease in patients with nonalcoholic fatty liver disease.
Xu HW; Hsu YC; Chang CH; Wei KL; Lin CL
Hepatol Int; 2016 Mar; 10(2):340-6. PubMed ID: 26676626
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
